Pseudomonas aeruginosa: An uncommon cause of diabetic foot infection

Journal of the American Podiatric Medical Association

Volumn 105, Issue 2, 2015, Pages 125-129

  Young, Heather ^a   Knepper, Bryan ^a   Hernandez, Whitney ^a   Shor, Asaf ^b   Bruntz, Merribeth ^a   Berg, Chrystal ^a   Price, Connie S ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLICATION; CROSS-SECTIONAL STUDY; DIABETIC FOOT; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUESTIONNAIRE; RETROSPECTIVE STUDY;

CROSS-SECTIONAL STUDIES; DIABETIC FOOT; HUMANS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES;

EID: 85016650048     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/0003-0538-105.2.125     Document Type: Article

References (22)

1. CITRON DM, GOLDSTEIN EJ, MERRIAM CV, et al: Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 45: 2819, 2007.
2. LIPSKY BA, TABAK YP, JOHANNES RS, et al: Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 53: 914, 2010.
3. Martinez-Gomez DDE A, Ramirez-Almagro C, CAMPILLOSOTO A, et al: Diabetic foot infections: prevalence and antibiotic sensitivity of the causative microorganisms [in Spanish]. Enferm Infecc Microbiol Clin 27: 317, 2009.
4. SHARMA VK, KHADKA PB, JOSHI A, et al: Common pathogens isolated in diabetic foot infection in Bir Hospital. Kathmandu Univ Med J (KUMJ) 4: 295, 2006.
5. ABDULRAZAK A, BITAR ZI, Al-Shamali AA, et al: Bacteriological study of diabetic foot infections. J Diabetes Complications 19: 138, 2005.
6. ERTUGRUL BM, ONCUL O, TULEK N, et al: A prospective, multi-center study: factors related to the management of diabetic foot infections. Eur J Clin Microbiol Infect Dis 31: 2345, 2012.
7. KANDEMIR O, AKBAY E, SAHIN E, et al: Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect 54: 439, 2007.
8. BANSAL E, GARG A, BHATIA S, et al: Spectrum of microbial flora in diabetic foot ulcers. Indian J Pathol Microbiol 51: 204, 2008.
9. El-Tahawy AT: Bacteriology of diabetic foot. Saudi Med J 21: 344, 2000.
10. RAJA NS: Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. J Microbiol Immunol Infect 40: 39, 2007.
11. SHANKAR EM, MOHAN V, PREMALATHA G, et al: Bacterial etiology of diabetic foot infections in South India. Eur J Int Med 16: 567, 2005.
12. AL BENWAN K, AL MULLA A, ROTIMI VO: A study of the microbiology of diabetic foot infections in a teaching hospital in Kuwait. J Infect Public Health 5: 1, 2012.
13. LIPSKY BA, BERENDT AR, CORNIA PB, et al: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54: e132, 2012.
14. LIPSKY BA, ITANI K, NORDEN C, et al: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillinsulbactam/ amoxicillin-clavulanate. Clin Infect Dis 38: 17, 2004.
15. GRAHAM DR, LUCASTI C, MALA FAIA O, et al: Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 34: 1460, 2002.
16. NOEL GJ, BUSH K, BAGCHI P, et al: A randomized, doubleblind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 46: 647, 2008.
17. LIPSKY BA, ARMSTRONG DG, CITRON DM, et al: Ertapanem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 366: 1695, 2005.
18. CDC/NHSN surveillance definitions for specific types of infections. Available at: http://www.cdc.gov/nhsn/PDFs/ pscManual/17pscNosInfDef_current.pdf. Accessed October 10, 2013.
19. HARRIS PA, TAYLOR R, THIELKE R, et al: Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Informatics 42: 377, 2009.
20. JENKINS TC, IRWIN A, COOMBS L, et al: Effects of clinical pathways for common outpatient infections on antibiotic prescribing. Am J Med 126: 327, 2013.
21. GOTTESMAN BS, CARMELI Y, SHITRIT P, et al: Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 49: 869, 2009.
22. BATARD E, OLLIVIER F, BOUTOILLE D, et al: Relationship between hospital antibiotic use and quinolone resistance in Escherichia coli. Int J Infect Dis 17: e254, 2013.